檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽

Description
* ( ) : : ; ; ; :R951.7 (712) :A : (2011) ResearchonOrphanDrugSalesModelofProfessionalPharmacyinU.S. XuYiWangYingxiaoandGongShiwei * (TongjiMedicalColegeHuazhong

Please download to get full document.

View again

of 5
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Information
Category:

Kids & Toys

Publish on:

Views: 4 | Pages: 5

Extension: PDF | Download: 0

Share
Transcript
* ( ) : : ; ; ; :R951.7 (712) :A : (2011) ResearchonOrphanDrugSalesModelofProfessionalPharmacyinU.S. XuYiWangYingxiaoandGongShiwei * (TongjiMedicalColegeHuazhong UniversityofScienceand TechnologyWuhan430030) ABSTRACT: Objective To explore Chinese orphan drug sales modelto promote orphan drug availability. Methods U.S.orphan drug sales modelofprofessionalpharmacy wasanalyzed bythe literatureresearchmethoddrawingonitssuccessfulexperiencemadetheselectionideafororphandrug salesmodeinchina.resultsinalusiontothesalescharacteristicsoforphandrugsuchasirregularlow demandhighphysicalandpsychologicalneedsmedicationhighpersonalizedmedicinetimelinessofdrug demandhighpricesandhighpurchasecosttheu.s.productioncirculationandenterprisesoforphan drugwereadoptdiferentmarketing methodstocommondrugssuchastheestablishmentofspecialized informationserviceplatformtosynchronizationofsalessalesdemonstrationsstafpromotionsservice promotionstargetingprofessionalsalesmailorderandpublicrelationsstrategiestargeted marketing. ConclusionIn ourcountryin each province or prefecture-levelcityto determinethe professional pharmacyandorphandrugproductionandreservesofthedirectorytotargetcustomerbaselocatedinthe rarepatientsdoctorsdrugmanufacturersinsurerstogethertoimproveorphandrugsaccessibility. KEY WORDS: professionalpharmacy;raredisease;salesmodel;orphandrug WHO WHO 5000 ~ % : ( ) : ; : ; Diplomat Pharmacy US Oncology (US ; OncologyCare Advantage) [2] (specialtypharmacyprograms) ; [1] [6] IMS Health [7] %20089 ~ (specialtypharmacy) 2 (Specialty Pharmaceuticals) (FDA) DavidA.Blaser [2] : [8] P.L.Sauerwald [4] 8 5 : [3] ; ; ( ); ; 6000 ~ ; ; :(1) WalgreensCVS (2) (3) [4] [9] (PBM) PBM [5] CVS Caremark Ⅱ MedcoExpress Scripts UnitedHealth (United ( ) ( Health Prescription Solutions) Aetna (Aetna ) Specialty) Walgreens (Walgreens Specialty) CVSCaremark United Health (Cimzia) (Humira) (Remicade) (Tysabri) (Pulmozyme) (Tobi) (Adagen) β- A(Fabrazyme) α1- (AAT)α1 (Aralast) (PKU) (BH4) Pompe/ Ⅱ VI(MPSVI) (Kuvan) (Kuvan) α- (Myozyme) (Naglazyme) 1 (HT-1) (Orfadin) (SBS) a-1 (Prolastin) (Ceredase) (Cerezyme) (Zavesca) (Zorbtive) Ⅱ ( ) (Elaprase) (Exjade) (MS) Ⅰ(MPS-I) dalfampridine(ampyra) β (Avonex) β -1b (Betaseron Extavia) (Copaxone) (Novantrone) β -1a (Rebif) (Tysabri) (Apokyn) (Adcirca) (Flolan) (Letairis) (Remodulin) (Revatio) (Tracleer) (Ventavis) (Aptivus) (Retrovir) AtriplaKaletra( )Truvada( ) (Aldurazyme) (Somavert) Ⅸ(Mononine) VI(NovoSeven) Ⅷ(Advate KogenateFS Xyntha) (VWD) / (Alphanate) ; ;Mail- ; (Robert Lauterborn) 4P 4Cs (Customer) (Cost) (Convenience) (Communication) 4Cs [11] ; ; ; ( ) [7] 4Cs 4 4P 4P (patients) (physicians) (payers) (pharmaceuticalmanufacturers) 3 24h [2] PBM [10] [7] 3 [4] 24h ; ; ; ( ; ; ; ( ); ( ; ; ); / / / ); ; ; ; ; ; ; ; ; ( ) : [1] 5 (4): (6): ; ; (6): ; [J] (2): [2] RowenaN.SchwartzKirbyJ.EngDeborah A.Frieze etal.nccn TaskForceReport:SpecialtyPharmacy [J]. National Comprehensive Cancer NetworkJuly [3] SuzanneSheley.RareDiseasesandOrphanDrugsLiftPhar- mainnovation [J].PharmaceuticalCommerce2010. [4] PamelaLeighSauerwald.ChangingtheChannel:Develop- mentsin US Specialty Pharmaceutical Distribution [J]. PharmaceuticalCommerce2009. [5] RitaShane.Managementofchronicdiseasesinthe21stcen- tury:theemergingroleofspecialtypharmacies [J].AmJ Health-SystPharm : [6] JamesA.Jorgenson.SpecialtyPharmacy:StatusandFuture Direction [J].TheAmericanJournalofPharmacyBenefits [7] BenComer.SpecialtyPharmaceuticals:ShiftingSpecialties [J].MedicalMarketingand Media2010. [8] DavidA.BlaserAndreaJ.LewtasMariaM.Ousterhout. Howto DefineSpecialtyPharmaceuticals-A SystematicRe- view [J]. The American Journalof Pharmacy Benefits [9] SeanD.Sulivan.ThePromiseofSpecialtyPharmaceuticals: AreThey WorththePrice[J].JournalofManagedCare Pharmacy (4)(Supplement):3-6. [10] SarahColin.SpecialtyPharmacy ManagementWilBecome MoreIntense [J]. Managed Care (10):20- [11] PennyBemus.BuildingAn AlternativeDistribution Model ForUltra-OrphanDisease [J].PharmaceuticalCommerce 檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽檽 ( 1234) [4].HPLC [J]. [J] (6): [5].HPLC [10]. [J] (1): [6]. [J] (4): [9] (2): [J] (8): [11]. [J]. [7] (4): HPLC [12].HPLC-UV-ELSD [J] (2): [8] [J] HPLC [J] (4): (11):
Similar documents
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks
SAVE OUR EARTH

We need your sign to support Project to invent "SMART AND CONTROLLABLE REFLECTIVE BALLOONS" to cover the Sun and Save Our Earth.

More details...

Sign Now!

We are very appreciated for your Prompt Action!

x